報價延遲最少15分鐘:2025/08/25 04:17 EDT
盤前時段
|
||||
|
5.29 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.35
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.79/-0.60
|
|
企業價值
497.06M
|
| 資產負債 |
|
每股賬面淨值
0.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
235.00K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 04:17 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause tofibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
